Arvee Laboratories (India) DuPont analysis

·UnclassifiedChart ›
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.89×1.04×0.75×0.57×0.67×
1.11×1.22×1.17×1.22×0.97×
10.0%6.3%6.4%4.9%10.1%
0.77×0.77×1.00×0.79×1.62×
1.28×1.28×1.22×1.32×1.38×
9.7%7.9%6.8%3.6%14.7%
7.8%7.8%7.1%3.7%15.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ARVEE₹182.00

Arvee Laboratories (India) Limited

· Unclassified
₹ CrorePeersSPCENETGVPTECHMCLNITIRAJASPINWALLJMASINTERCOMMcap ₹201 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.670.570.751.040.89
Interest Burden (Pretax/EBIT) ×0.971.221.171.221.11
EBIT Margin %10.144.946.406.309.96
Asset Turnover ×1.620.791.000.770.77
Financial Leverage (Assets/Equity) ×1.381.321.221.281.28
ROE (5-step product, year-end total equity) %14.723.636.817.909.68
ROE (owners' profit / average owners' equity) %15.843.687.117.777.77
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.